Canavan disease

Infobox_Disease
Name = Canavan disease


Caption =
DiseasesDB = 29780
ICD10 = ICD10|E|75|2|e|70
ICD9 = ICD9|330.0
ICDO =
OMIM = 271900
MedlinePlus = 001586
eMedicineSubj =
eMedicineTopic =
MeshID = D017825

Canavan disease, also called Canavan-Van Bogaert-Bertrand disease, aspartoacylase deficiency or aminoacylase 2 deficiency, [OMIM|271900] is an autosomal recessive [cite journal |pmid=16647192 |year=2006 |month=Jun |author=Namboodiri, Am; Peethambaran, A; Mathew, R; Sambhu, Pa; Hershfield, J; Moffett, Jr; Madhavarao, Cn |title=Canavan disease and the role of N-acetylaspartate in myelin synthesis |volume=252 |issue=1-2 |pages=216–23 |doi=10.1016/j.mce.2006.03.016 |journal=Molecular and cellular endocrinology] degenerative disorder that causes progressive damage to nerve cells in the brain. This disease is one of a group of genetic disorders called leukodystrophies.

Leukodystrophies are characterized by degeneration of myelin in the phospholipid layer insulating the axon of a neuron. The gene associated with the disorder is located on human chromosome 17.

History

Canavan disease was first described in 1931 by Myrtelle Canavan. [cite journal |author=Canavan MM |title=Schilder's encephalitis periaxialis diffusa. Report of a case in a child aged sixteen and one-half months |journal=Archives of Neurology and Psychiatry |volume=25 |pages=299–308 |year=1931 ]

Prevalence

Although Canavan disease may occur in any ethnic group, it affects persons of Eastern European Jewish ancestry more frequently. About 1/40 individuals of Eastern European (Ashkenazi) Jewish ancestry are carriers.

Pathophysiology

Canavan disease is inherited in an autosomal recessive fashion. When both parents are carriers, there is a 25% chance of having an affected child. Genetic counseling and genetic testing is recommended for families with two parental carriers.

Canavan disease is caused by a defective "ASPA" gene which is responsible for the production of the enzyme aspartoacylase. This enzyme breaks down the concentrated brain molecule "N"-acetyl aspartate. Decreased aspartoacylase activity prevents the normal breakdown of N-acetyl aspartate, and the lack of breakdown somehow interferes with growth of the myelin sheath of the nerve fibers in the brain. The myelin sheath is the fatty covering that surrounds nerve cells and acts as an insulator, which allows for efficient transmission of nerve impulses.

ymptoms

Symptoms of Canavan disease, which appear in early infancy and progress rapidly, may include mental retardation, loss of previously acquired motor skills, feeding difficulties, abnormal muscle tone (i.e., floppiness or stiffness), poor head control, and megalocephaly (abnormally enlarged head). Paralysis, blindness, or seizures may also occur.

Treatment

There is no cure for Canavan disease, nor is there a standard course of treatment. Treatment is symptomatic and supportive.

Prognosis

Death usually occurs before age 4 without treatment. Some children may survive into their twenties via newer treatments which have extended life expectancy.Fact|date=October 2007 There is no known cure.

Current research

Research involving triacetin supplementation has shown promise in a mouse model.cite journal |author=Mathew R, Arun P, Madhavarao CN, Moffett JR, Namboodiri MA
title=Progress toward acetate supplementation therapy for Canavan disease: glyceryl triacetate administration increases acetate, but not N-acetylaspartate, levels in brain |journal=J. Pharmacol. Exp. Ther. |volume=315 |issue=1 |pages=297–303 |year=2005 |pmid=16002461 |doi=10.1124/jpet.105.087536 |url=http://jpet.aspetjournals.org/cgi/reprint/315/1/297.pdf ] Triacetin, which can be enzymatically cleaved to form acetate, enters the brain more readily than the negatively charged acetate.

A team of researchers headed by Paola Leone are currently at the University of Medicine and Dentistry of New Jersey, in Camden, New Jersey. The brain gene therapy is conducted at Cooper University Hospital. The procedure involves the insertion of six catheters into the brain that deliver a solution containing 600 billion to 900 billion engineered virus particles. The virus, a modified version of AAV, is designed to replace the aspartoacylase enzyme.cite journal |pmid=12162821 |doi=10.1089/104303402760128612 |year=2002 |month=Jul |author=Janson, C; Mcphee, S; Bilaniuk, L; Haselgrove, J; Testaiuti, M; Freese, A; Wang, Dj; Shera, D; Hurh, P; Rupin, J; Saslow, E; Goldfarb, O; Goldberg, M; Larijani, G; Sharrar, W; Liouterman, L; Camp, A; Kolodny, E; Samulski, J; Leone, P |title=Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain |volume=13 |issue=11 |pages=1391–412 |journal=Human gene therapy ] Children treated with this procedure to date have shown marked improvements, including the growth of myelin with decreased levels of the n-acetyl-aspartate toxin.Fact|date=October 2007

ee also

*The Myelin Project
*The Stennis Foundation
*Canavan

External links

* [http://www.ninds.nih.gov/disorders/canavan/canavan.htm Information on the disorder from the National Institute of Neurological Disorder and Stroke]
* [http://www4.umdnj.edu/cgtcweb/ Cell & Gene Therapy Center at UMDNJ]
* [http://www.canavanresearch.org/ Canavan Research Illinois - A public charity devoted to curing Canavan disease]
* [http://www.canavan.org/ Canavan Research - A foundation devoted to curing Canavan disease]

References